A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

NCT ID: NCT01487109

Last Updated: 2021-08-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to evaluate the safety and efficacy of treatment with CTP-499 for 24 weeks in patients with chronic kidney disease, Type 2 diabetic nephropathy and who are currently receiving treatment with an angiotensin converting enzyme inhibitor (ACEI) and/or angiotensin II receptor blocker (ARB).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There are two parts to this study, each part includes double-blind treatment with either CTP-499 or placebo. Part 1 will evaluate the safety and efficacy of treatment with CTP-499 twice daily for 24 weeks. Part 2 will evaluate the effects of longer term dosing for an additional 24 weeks. Following Part 2, patients will be allowed to participate in an Open Label extension with CTP-499 for a period of an additional 48 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

matching placebo tablets

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo tablet

CTP-499

600 mg tablet

Group Type ACTIVE_COMPARATOR

CTP-499

Intervention Type DRUG

600 mg tablet twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CTP-499

600 mg tablet twice daily

Intervention Type DRUG

Placebo

Matching placebo tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female 18 years or older
* Patient diagnosed with Type 2 diabetes mellitus and chronic kidney disease
* On a stable regimen of ACE inhibitors and/or ARB drugs for a minimum of 4 weeks
* Not expected to start dialysis for one year
* Patient has blood pressure less than or equal to 145/90 mm Hg
* Patient has UACR greater than or equal to 200 mg/g if male and 300 mg/g if female but not more than 5000 mg/g
* Patient has glycosylated hemoglobin A1c less than or equal to 10.5%

Exclusion Criteria

* Patient has concurrent condition such as uncontrolled inflammatory disease, acute infection or other unstable illnesses
* Patient has a history of allergy or sensitivity to pentoxifylline or methylxanthines
* Patient has acute, active and/or unstable renal impairment or has been hospitalized for acute renal failure within the previous year
* Patient has active malignancy or history of neoplastic disease
* Patient has a QTc interval greater than 450 milliseconds
* Patient has ALT or AST greater than 3 times the upper limit of normal or a potassium greater than or equal to 5.5mEq/L at screening
* Patient is breast feeding or pregnant
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Concert Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

LuAnn Sabounjian

Role: STUDY_DIRECTOR

Concert Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Agave Clinical Research

Tempe, Arizona, United States

Site Status

Harrisburg Family Medical Center

Harrisburg, Arkansas, United States

Site Status

Arkansas Primary Care Clinic

Little Rock, Arkansas, United States

Site Status

Providence Clinical Research

Burbank, California, United States

Site Status

California Institute of Renal Research

Chula Vista, California, United States

Site Status

SC Clinical Research

Garden Grove, California, United States

Site Status

Premiere Clinical Research

Lakewood, California, United States

Site Status

Long Beach Center for Clinical Research

Long Beach, California, United States

Site Status

Premiere Clinical Research

Long Beach, California, United States

Site Status

UCLA Kidney Transplant Research

Los Angeles, California, United States

Site Status

David Geffen School of Medicine Division of Nephrology

Los Angeles, California, United States

Site Status

Desert Oasis Healthcare Medical Group

Palm Springs, California, United States

Site Status

Apex Research of Riverside

Riverside, California, United States

Site Status

River City Clinical Research

Sacramento, California, United States

Site Status

California Institute of Renal Research

San Diego, California, United States

Site Status

Samsun Clinic

Santa Barbara, California, United States

Site Status

Orange County Research Center

Tustin, California, United States

Site Status

Infosphere Clinical Research

West Hills, California, United States

Site Status

Creekside Endocrine Associates

Denver, Colorado, United States

Site Status

Palm Spring Research Institute

Hialeah, Florida, United States

Site Status

San Marcus Research Clinic, Inc.

Miami, Florida, United States

Site Status

Advanced Pharma CR

Miami, Florida, United States

Site Status

Ormond Medical Arts Pharmaceutical Research

Ormond Beach, Florida, United States

Site Status

Clincal Research of Central Florida

Winter Haven, Florida, United States

Site Status

River Birch Research Alliance

Blue Ridge, Georgia, United States

Site Status

Apex Medical Research

Chicago, Illinois, United States

Site Status

University of Chicago Medical Center

Chicago, Illinois, United States

Site Status

American Health Network of IN

Avon, Indiana, United States

Site Status

American Healthcare Network of Indiana

Greenfield, Indiana, United States

Site Status

Medstar Health Research Institute

Hyattsville, Maryland, United States

Site Status

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

Harvard Medical School Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Apex Medical Research MI

Flint, Michigan, United States

Site Status

Clinical Research Consultants (MO)

Kansas City, Missouri, United States

Site Status

The Rogosin Institute

New York, New York, United States

Site Status

Clinical Research Development Associates (NY)

Rosedale, New York, United States

Site Status

University of North Carolina School of Medicine

Chapel Hill, North Carolina, United States

Site Status

Clinical Research Limited

Canton, Ohio, United States

Site Status

Lynn Institute of Norman

Norman, Oklahoma, United States

Site Status

C.S.R.A. Renal Services

Aiken, South Carolina, United States

Site Status

Pharmacorp Clinical Trials

Charleston, South Carolina, United States

Site Status

Mountain View Clinical Research

Greer, South Carolina, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Millenium Clinical Research

Houston, Texas, United States

Site Status

Research Across America

Houston, Texas, United States

Site Status

Renal Associates

San Antonio, Texas, United States

Site Status

Panacea Clinical Research

San Antonio, Texas, United States

Site Status

Cetero

San Antonio, Texas, United States

Site Status

Multicare Research Institute (WA)

Tacoma, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP505.2001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.